Tramadol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Tramadol: Acromesomelic dysplasia, Hunter-Thompson type
One-Sentence Summary
Tramadol is an opioid/SNRI-type analgesic, originally associated with osteoarthritis and arthropathy pain. The TxGNN model predicts it may be effective for acromesomelic dysplasia, Hunter-Thompson type, a rare genetic skeletal disorder, but there are currently 0 clinical trials and 0 publications supporting this prediction. It is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, tramadol is a centrally acting analgesic with mu-opioid agonist and monoamine reuptake inhibition activity, and it is used for pain in joint conditions such as osteoarthritis.
Acromesomelic dysplasia, Hunter-Thompson type, is a rare genetic skeletal dysplasia caused by loss-of-function variants in the CDMP1/GDF5 gene, affecting limb growth. Tramadol does not act on the GDF5/BMP pathway, so there is no credible mechanistic link. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. At most, tramadol could offer symptomatic analgesia, which is not a disease-modifying indication.
Other top-ranked predictions show the same pattern. They include brachyolmia, myosclerosis, pseudoachondroplasia, spondyloarthropathy and several forms of juvenile arthritis. Only pseudoachondroplasia, which is associated with early-onset osteoarthritis, and the arthritis-related conditions have a weak, indirect symptomatic connection through joint pain management.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the top-ranked prediction.
For context, the only publication identified in the wider prediction set is for juvenile idiopathic arthritis (rank 7):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 20799760 | 2010 | Review | Paediatric Drugs | Review of ketoprofen (an NSAID) pharmacokinetics, efficacy and tolerability in children. It concerns ketoprofen, not tramadol, so it gives no direct evidence for this drug. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 12008B | Tramal | Capsule containing tramadol hydrochloride 50 mg (oral) | Not available in the data compiled for this report |
Safety Considerations
- Contraindications and conditions of concern (from knowledge graph drug-disease links, not label text): hypertension, liver failure, liver disease, cirrhosis, gallbladder disease, epilepsy, anxiety disorder, neurotic disorder, dysthymic disorder, diabetes mellitus, diabetic ketoacidosis, substance abuse/dependence, substance-related disorder, hyperlipidaemia, familial hyperlipidaemia, respiratory failure, paracetamol poisoning, serotonin syndrome, pseudotumor cerebri, intracranial hypertension, alcohol withdrawal, Wernicke-Korsakoff syndrome, substance withdrawal syndrome, and central nervous system infectious disorders.
- Drug Interactions: 100 interactions were recorded. The first 20 listed include the following.
- Major: alvimopan, bupropion, cisapride, dexfenfluramine, diethylpropion, dolasetron, dronabinol, ephedrine, fenfluramine.
- Moderate: atropine, bisacodyl, castor oil, cimetidine, clarithromycin, clidinium, dicyclomine, eliglustat, eluxadoline, famotidine, glycerin.
- Paediatric use: Several top predictions involve juvenile arthritis. Tramadol carries paediatric safety restrictions, including respiratory depression risk and CYP2D6 ultra-rapid metabolism, which would need careful review.
Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is a computational signal only (L5). There are no registered trials or supporting publications, and no plausible mechanistic link between tramadol and GDF5-related skeletal dysplasia. Any benefit would be limited to symptomatic pain relief, which is already within tramadol’s existing analgesic use.
To proceed, the following is needed:
- Mechanism of action data (MOA) to enable a proper mechanistic-link analysis
- TGA Product Information for the ARTG entry, including approved indications, warnings and contraindications
- Preclinical or clinical evidence showing a disease-relevant effect in the predicted condition
- A decision on whether symptomatic analgesia in rare skeletal or arthritic conditions is a useful question, since a disease-modifying claim is not supported
- A dedicated paediatric safety review before any use in juvenile arthritis
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.